April 16 (Reuters) - Abbott Laboratories ABT.N beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices.
The company also maintained its full-year profit forecast of $5.05 to $5.25 per share in the face of an escalating global trade war.
Abbott is likely to face a hit from the heavy duties imposed on other countries given its broad manufacturing footprint across the world, according to analysts.
On an adjusted basis, the company's quarterly profit of $1.09 per share beat analysts' average expectations of $1.07 per share, according to estimates compiled by LSEG.
(Reporting by Christy Santhosh and Puyaan Singh in Bengaluru; Editing by Leroy Leo)
((Christy.Santhosh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。